This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuits Against SciClone Pharmaceuticals, Inc.

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action lawsuits have been brought on behalf of purchasers of the common stock of SciClone Pharmaceuticals, Inc. (“SciClone”) (Nasdaq:SCLN) between May 11, 2009 and August 10, 2010, inclusive (“Class Period”).

If you purchased SciClone common stock during the Class Period, you may move the Court for appointment as lead plaintiff by no later than October 12, 2010. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in this action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in this action.

SciClone shareholders that wish to learn more about this action and how to seek appointment as lead plaintiff should visit Lieff Cabraser’s website at http://www.lieffcabraser.com/cases.php?CaseID=342 or contact attorney Sharon Lee toll free at (800) 541-7358.

Background on SciClone Securities Class Litigation

The actions, pending in the United States District Court for the Northern District of California, were brought against SciClone and certain of its officers for violations of the Securities Exchange Act of 1934. SciClone, headquartered in Foster City, California, is engaged in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases.

The complaints in the above-mentioned actions allege that during the Class Period, defendants failed to disclose that SciClone engaged in illegal and improper sales and marketing activities in China and elsewhere. In addition, the actions allege that defendants failed to disclose that SciClone’s financial results and business prospects during the Class Period were attributable, in part, to the wrongful conduct.

On August 9, 2010, after the close of trading, SciClone disclosed that the Securities and Exchange Commission had initiated a formal investigation of the Company and requested information relating to matters including interactions with regulators and government-owned entities in China, activities relating to sales in China and documents relating to certain Company disclosures. SciClone also disclosed that the Department of Justice had received information about the Company’s practices that suggested violations of the Foreign Corrupt Practices Act. On this news, the price of SciClone common stock fell $1.03 per share, or approximately 29 percent, from its closing price on August 9, 2010 to close at $2.48 per share on August 10, 2010, on unusually high trading volume.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,031.14 +43.63 0.26%
S&P 500 1,984.13 -1.41 -0.07%
NASDAQ 4,518.9020 -48.6960 -1.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs